Welcome to our dedicated page for Nascent Biotech news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech stock.
About Nascent Biotech (NBIO)
Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotechnology company specializing in the development of human monoclonal antibodies for the treatment of various cancers. Founded in 2014, the company is pioneering immunotherapy solutions to address critical unmet medical needs, with a primary focus on brain and pancreatic cancers. Its lead candidate, Pritumumab (PTB), is a human monoclonal antibody currently in Phase II clinical trials for the treatment of brain cancer, including glioblastomas, one of the most aggressive and challenging forms of cancer to treat.
Core Technology and Scientific Approach
Nascent Biotech’s innovative approach is rooted in the science of immunotherapy, which seeks to harness and modulate the body’s natural immune response to fight disease. The company’s expertise lies in monoclonal antibodies (mAbs), which are highly specific proteins designed to bind to unique antigens on the surface of cancer cells. Pritumumab, for instance, targets a proprietary antigen expressed on cancer cells, enabling precise and effective treatment while minimizing damage to healthy tissues. This targeted approach distinguishes Nascent Biotech in the competitive oncology landscape.
Pipeline and Clinical Advancements
Nascent Biotech’s clinical development is centered on Pritumumab, which has demonstrated promising safety and efficacy results in Phase I trials. These trials showed no dose-related toxicities and highlighted significant tumor shrinkage in some patients, particularly those with glioblastomas. The ongoing Phase II trials aim to evaluate clinical outcomes further, including monotherapy and combination therapies with chemotherapy and checkpoint inhibitors. Additionally, the company is exploring expanded access trials to assess Pritumumab’s potential in treating other cancers, such as pancreatic and colorectal cancers.
Innovative Drug Delivery Mechanisms
In collaboration with HypoSpray Pharma, Nascent Biotech is working to develop alternative delivery systems for Pritumumab. This partnership aims to eliminate the need for bi-weekly infusion treatments, offering patients a more convenient, transdermal or transmucosal drug delivery option. Such innovations not only improve patient quality of life but also enhance the accessibility and scalability of cancer treatments.
Market Position and Competitive Landscape
Nascent Biotech operates in the highly competitive and rapidly evolving field of oncology-focused biotechnology. Its focus on hard-to-treat cancers like glioblastomas and pancreatic cancer positions it within a niche market with significant unmet needs. Competitors include other biotech firms specializing in immunotherapy, such as those developing CAR-T therapies, checkpoint inhibitors, and other monoclonal antibodies. Nascent Biotech differentiates itself through its proprietary antigen-targeting technology and its emphasis on innovative drug delivery solutions.
Challenges and Opportunities
As a clinical-stage company, Nascent Biotech faces challenges typical of its industry, including securing funding for ongoing trials, navigating complex regulatory pathways, and achieving commercial viability. However, its focus on high-value targets, such as brain and pancreatic cancers, and its commitment to innovation provide significant opportunities for growth and partnerships. The company’s Orphan Drug Designation for pancreatic cancer further underscores its potential to address critical medical needs in underserved markets.
Conclusion
Nascent Biotech represents a compelling player in the biotechnology sector, leveraging its expertise in monoclonal antibody development to tackle some of the most challenging cancers. With a strong scientific foundation, innovative partnerships, and a focus on patient-centered solutions, the company is well-positioned to make meaningful contributions to the field of oncology. Its ongoing clinical advancements and collaborative efforts highlight its commitment to improving patient outcomes and addressing unmet medical needs.
Nascent Biotech (OTCQB:NBIO) and BioRay Pharmaceutical Ltd have signed a licensing agreement granting BioRay exclusive rights to commercialize Nascent's monoclonal antibody, Pritumumab, in international markets outside North and Central America. Nascent will receive USD $5 million in total, with an initial payment of USD $1 million already received. The agreement also includes milestone payments tied to clinical trial progress. Both companies aim to address unmet medical needs in cancer treatment through this collaboration.
Nascent Biotech (OTCQB:NBIO) has successfully settled its convertible note liability with Harbor Gate Capital LLC, eliminating a potential dilution risk for shareholders. The settlement involved a total value of $115,000, covering principal, accrued interest, and prepayment. As a result, the company has almost eradicated outstanding dilution risks associated with previous funding rounds. Additionally, all preferred shares from prior convertible financing have been converted, with only one convertible note remaining, due in August 2021.
Nascent Biotech, Inc. (OTCQB:NBIO) has successfully eliminated a significant convertible debt of over $186k held by JSJ Investments, LLC. This proactive measure prevents potential dilution of shares that could arise from the conversion of this debt into common shares at a discounted rate. CEO Sean Carrick emphasized the company’s commitment to shareholder value and reducing uncertainty in its financial standing. Nascent Biotech is focused on developing monoclonal antibodies for treating various cancers and viral infections, with ongoing clinical trials for their lead candidate, Pritumumab.
Nascent Biotech (OTCQB:NBIO) has initiated patient dosing in its Phase I clinical trial for Pritumumab (PTB), aimed at treating brain cancer including malignant tumors and brain metastases. This milestone is crucial for assessing PTB's safety and efficacy. The antibody targets cancer cells by binding to vimentin, offering a potential alternative to traditional chemotherapy. As enrollment continues, the trial may influence future studies for common cancers like breast and lung cancer. For more information, visit ClinicalTrials.gov.
Nascent Biotech has commenced its Phase I clinical trial for Pritumumab (PTB), focusing on treating brain cancer, including malignant primary brain tumors and brain metastases. The trial aims to evaluate PTB's effectiveness as a targeted immunotherapy, which selectively targets cancer cells without affecting healthy cells. Screening for patient enrollment is ongoing. This trial could open pathways for treating various cancers, given that the antibody binds to a protein present in multiple cancer types. For more details, visit clinicaltrials.gov.
Nascent Biotech (OTCQB:NBIO) has received a Method-of-Use patent from the USPTO for its monoclonal antibody, Pritumumab (PTB). This patent highlights PTB's ability to cross the Blood-Brain Barrier (BBB), enhancing its potential as both a monotherapy and a carrier for other treatments. The approval strengthens the company's intellectual property and market position, crucial for its expansion in cancer and viral therapies. CEO Sean Carrick emphasized the significance of this patent for potential market impact and future updates for shareholders.
Nascent Biotech (OTCQB:NBIO) has reported promising results from its collaboration with Syracuse University, showcasing that its monoclonal antibody, Pritumumab (PTB), effectively blocked 80% of viral entry into cells. This breakthrough allows PTB to advance to laboratory-based animal studies, potentially aiding in COVID-19 treatment. The research highlights PTB's mechanism of action by targeting cell-surface vimentin to inhibit SARS2 entry. The company also launched a Phase I Clinical Trial for Brain Cancer at Hoag Family Cancer Institute, showing commitment to developing treatments for cancers and viral infections.
Nascent Biotech (OTCQB:NBIO) has announced positive initial In-Vitro study results in collaboration with Syracuse University, demonstrating that Pritumumab (PTB) effectively blocks viral entry of SARS-CoV-2. This antibody, known for its cancer-fighting properties, shows potential for further development in tackling COVID-19. Senior Medical Consultant Dr. Navpaul Singh emphasized that less viral load correlates with reduced patient symptoms, suggesting PTB could be used in combination therapies. The company is also advancing its Phase I Brain Cancer Clinical Trial.
Nascent Biotech, Inc. (OTCQB:NBIO) announced crucial additions to its team as it prepares for Phase One clinical trials of its monoclonal antibody, Pritumumab (PTB), aimed at treating brain cancer. Effective November 1, 2020, Douglas Karas steps in as Chief Operating Officer, while Dr. Ivan Babic joins as Consulting Director of Research. These changes aim to enhance the company’s expertise in oncology. The trials are set to advance Nascent Biotech’s position in the cancer treatment sector.
Nascent Biotech, Inc. (OTCQB:NBIO) has successfully reduced its liabilities, decreasing convertible note principal from $161,250 to $11,250, achieving a total reduction of $150,000. This debt reduction strengthens the company's financial position, allowing it to focus on upcoming clinical trials for its lead candidate, Pritumumab (PTB), targeting brain and pancreatic cancers. The trials are set to begin soon, with additional development for COVID-19 treatments also underway.
FAQ
What is the current stock price of Nascent Biotech (NBIO)?
What is the market cap of Nascent Biotech (NBIO)?
What does Nascent Biotech specialize in?
What is Pritumumab?
How does Nascent Biotech differentiate itself in the biotech industry?
What challenges does Nascent Biotech face?
What are monoclonal antibodies?
What is the significance of Nascent Biotech’s collaboration with HypoSpray Pharma?
What cancers is Nascent Biotech targeting?
What is the status of Pritumumab’s clinical trials?
Does Nascent Biotech have any special designations for its treatments?
What is immunotherapy?
